Connective tissue growth factor or CTGF is a revolutionary cysteine-rich, secreted peptide, which is concerned in human atherosclerosis and fibrotic disorders for instance systemic scleroderma. It is an adherent of the peptide family that contains serum-induced immediate early gene products, a putative proto-oncogene and a v-src–induced peptide. The CTGF gene family is a modular protein and is preserved throughout evolution. CTGF mRNA has been found in the mouse, chicken, human, frog, and fly. Key functions of the CTGF gene family include wound healing, embryogenesis and regulation of extracellular matrix production. Human connective tissue growth factor is undetectable in normal blood vessels but overexpressed in atherosclerotic injuries.
According to study, “Global Connective Tissue Growth Factor Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use” the key companies operating in the global connective tissue growth factor market are BLR Bio LLC, ProMetic Life Sciences Inc., RXi Pharmaceuticals Corp., Hoffmann-La Roche Ltd., FibroGen Inc., Eli Lilly and Company, Abbott Laboratories, AutoImmune Inc., Bayer AG, Biogen, Pfizer, AstraZeneca, Johnson & Johnson, LUPIN, Amgen Inc.
Based on product type, connective tissue growth factor market is segmented into BLR-200, OLX-201, IB-DMD, PBI-4050 and others. Based on diagnosis, market is segmented into X-ray examination, physical examination, ANA (Antinuclear Antibody Test), and others. Based on treatment, market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, cortisone drugs or steroids, cytotoxic drugs, and others. Based on application, market is segmented into hypertrophic scars, genetic disorders, liver fibrosis, opthalmology and others. In addition, based on end-user, market is segmented into diagnostic clinics, hospital, and others.
The connective tissue growth factor market is driven by increase in the research & development (R&D) efforts to find treatment or cure for connective tissue disease, followed by rise in prevalence of connective tissue disease across the globe especially in women, increase in awareness & rise in acceptance among the general population about connective tissue diseases, growth in expenditure on healthcare and high unmet medical needs of the current treatment. However, lack of funds in middle & low-income countries, inadequate R&D infrastructure and lack of a knowledgeable workforce may impact the market. Moreover, growth in support from governments across the world along with rise in funds for R&D from the private industry is a key opportunity for market.
Based on geography, the North-American region holds major share in connective tissue growth factor market owing to increase in healthcare expenditure and rise in awareness among people about treatment of connective tissue disease in the region. Whereas, the European region is anticipated to exhibit substantial growth rate due to growth in improvement in reimbursement policies in healthcare over the forecast period. The Asian-Pacific region is also anticipated to exhibit substantial growth rate as a result of rise in developing healthcare technology and huge patient pool over the forecast period. In near future, it is expected that the market will be reached at rapid pace on account of rise in diagnosed and drug-treated population during the forecast period.
For More Information, click on the link below:-
Ankur Gupta, Head Marketing & Communications